COMP <GO>
PHAT vs EOLS // OPERATING MARGIN
Phathom Pharmaceuticals Inc. (NASDAQ) VS. Evolus Inc. (NASDAQ) • 15-METRIC TALLY: PHAT 4
— EOLS 2
▲ OPERATING MARGIN LEADER: EOLS
LAST: $6.22 (-0.95%) • MKT CAP: $503.2M
operating-margins
-60.00%
LAST: $7.52 (-1.51%) • MKT CAP: $496.7M
operating-margins
-11.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PHAT VS. EOLS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PHAT | EOLS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.10% | 66.30% | +20.80 | PHAT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -9.20% | — | TIE | /fcf-yield <GO> |
| Operating Margin ACTIVE | -60.00% | -11.00% | -49.00 | EOLS | /operating-margins <GO> |
| Net Profit Margin | -0.10% | -17.40% | +17.30 | PHAT | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 11.60% | +168.40 | PHAT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 4/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 33.5 | 46.1 | -12.63 | EOLS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $503.2M | $496.7M | $6.5M | PHAT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PHAT REV | EOLS REV | PHAT GROSS % | EOLS GROSS % | PHAT FCF | EOLS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $175.1M | $297.2M | 87.1% | 66.3% | -$167.0M | -$45.7M |
| FY 2024 | $55.3M | $266.3M | 85.6% | 68.5% | -$266.9M | -$19.5M |
| FY 2023 | $682.0K | $202.1M | — | — | -$137.6M | -$34.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PHAT // BETA —
EOLS // BETA —